首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1812530

血友病治疗市场按产品类型、通路和地区划分

Hemophilia Treatment Market, By Product Type, By Distribution Channel, and By Region

出版日期: 2025年08月11日 | 出版商:

Coherent Market Insights | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

简介目录

血友病治疗市场规模预计在 2025 年达到 171.829 亿美元，预计到 2032 年将达到 264.051 亿美元，2025 年至 2032 年的复合年增长率为 6.33%。

报告范围		报告详细信息
基准年	2024	2025年的市场规模	171.829亿美元
效能数据	2020-2024	预测期	2025-2032
预测期间（2025-2032年）的复合年增长率：	6.33%	2032年预测	264.051亿美元

血友病是一种遗传性出血性疾病，其特征是缺乏或缺乏称为凝血因子（例如凝血因子 VIII）的蛋白质。大约有 13 种凝血因子，它们与血小板协同作用，帮助血液凝固。血友病分为三种：A、B 和 C。A型血友病 A是最常见的类型，由凝血因子 VIII 缺乏引起。B型血友病由凝血因子 IX 缺乏引起，血友病 C 由凝血因子 XI 缺乏引起。在大多数情况下，血友病具有家族遗传性。血友病的主要治疗方法是静脉注射凝血因子。然而，血友病治疗的高昂费用、药物短缺以及与血浆衍生产品相关的严重不利事件预计将阻碍市场成长。因此，预计在预测期内，血友病发病率和盛行率的上升将推动市场成长。为了解决这个问题，主要企业正在推出产品来满足尚未满足的消费者需求。有关产品发布和治疗的有利监管环境和指导方针是预计在预测期内推动市场成长的其他因素。

市场动态

预计预测期内，政府加大血友病治疗力度的倡议将推动血友病治疗市场的成长。例如，根据美国国家医学图书馆2021年6月发表的一篇文章，世界血友病联盟 (WFH) 已开始透过其人道主义援助计画向中低收入国家分发凝血因子浓缩物和艾美珠单抗，以改善开发中国家有限数量的血友病患者的生活。

本次调查的主要特点

本报告对全球血友病治疗市场进行了详细分析，并以 2024 年为基准年，提供了预测期 2025-2032 的市场规模（百万美元）和年复合成长率(CAGR)。
它还强调了各个领域的潜在商机，并说明了针对该市场的引人注目的投资提案。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
它根据公司亮点、产品系列、关键亮点、财务表现和策略等参数，对全球血友病治疗市场的主要企业进行了概述。
本报告的见解将使负责人和企业经营团队能够就未来的产品发布、新兴车型、市场扩张和行销策略做出明智的决策。
全球血友病治疗市场报告涉及该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
相关人员可以透过用于分析全球血友病治疗市场的各种策略矩阵来促进决策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 17,182.9 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	6.33%	2032 Value Projection:	USD 26,405.1 Mn

Hemophilia is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor such as factor VIII. There are around 13 types of clotting factors that work with blood platelets to help in clotting of blood. There are three forms of hemophilia - A, B, and C. Hemophilia A is the most common form and is caused due to deficiency of factor VIII. Hemophilia B occurs due to deficiency of factor IX, and Hemophilia C is caused due to factor XI deficiency.In most cases, hemophilia is passed down through families that are inherited. It is mostly passed to the male childrens. The primary treatment for hemophilia is to replace the clotting factor in the blood though intravenous infusions. However, high cost of hemophilia treatment, lack of medicines and serious adverse events associated with plasma derived derived products is expected to hinder the market growth. Consequently, rising incidence and prevalence of hemophilic disorders are expected to boost growth of the market over the forecast period. This has led to product launches by key players to fulfill the unmet needs of consumers. Favorable regulatory scenarios and guidelines for the product launches and treatment are other factors that are expected to propel growth of the market over the forecast period.

Market Dynamics

Increasing government initiatives towards hemophilia treatment is likely expected to propel the growth of hemophilia treatment market over the forecast period. For instance, according to the article published in National Library of Medicine in June 2021, World Federation of Hemophilia(WFH) started distribution of coagulation factor concentrates and emicizumab in low- and low-middle-income countries through a humanitarian aid program. This programwill hwlp to improve life of a limited number of PWH in the developing world.

Key features of the study

This report provides an in-depth analysis of the global hemophilia treatment market and provides market size (USD Mn) and compound annual growth rate (CAGR) for the forecast period 2025-2032, considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global hemophilia treatment market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Takeda Pharmaceutical Co., Ltd., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, and F. Hoffmann-La Roche AG.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global hemophilia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hemophilia treatment market.

Market Segmentation

Global Hemophilia Treatment Market, By Product Type
- Plasma Derived Coagulation Factor
- Recombinant Coagulation Factor
- Antifibrinolytic Agents
- Desmopressin
Global Hemophilia Treatment Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Hemophilia Treatment Market, By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Company Profiles
- Takeda Pharmaceutical Co., Ltd.
- Sanofi S.A.
- Octapharma AG
- Swedish Orphan Biovitrum AB
- Baxter International Inc.
- Biogen Inc
- Bayer AG
- CSL Behring
- Ferring B.V.
- Pfizer, Inc.
- Kedrion
- Novo Nordisk A/S
- F. Hoffmann-La Roche AG

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Hemophilia Treatment Market, By Product Type, 2020 - 2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
Recombinant Coagulation Factor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
Plasma Derived Coagulation Factor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
Antifibrinolytic Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
Desmopressin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)

5. Global Hemophilia Treatment Market, By Distribution Channel, 2020 - 2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)

6. Global Hemophilia Treatment Market, By Region, 2020 - 2032, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021-2032
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Takeda Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Octapharma AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Swedish Orphan Biovitrum AB
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Baxter International Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Biogen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
CSL Behring
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Ferring B.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Kedrion
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
F. Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies

8. Section

Research Methodology
About Us

02-2729-4219

+886-2-2729-4219

License/价格

血友病治疗市场按产品类型、通路和地区划分

Hemophilia Treatment Market, By Product Type, By Distribution Channel, and By Region

市场动态

目录

第一章研究目标与前提

第二章市场展望

第三章：市场动态、法规与趋势分析

4. 2020-2032 年全球血友病治疗市场（依产品类型）

5. 2020-2032 年全球血友病治疗市场（依通路）

6. 2020-2032 年全球血友病治疗市场（按地区）

第七章竞争态势

第 8 章章节